Overview

A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status:
Recruiting

Trial end date:
2028-01-30

Target enrollment:

Participant gender:

Summary

This is a 1:1 randomized, open label, multi-center phase II trial to evaluate the safety, dosing, efficacy, and biological activity of adding GEN-1 to chemotherapy + BEV compared to chemotherapy + BEV alone.

Phase:

Phase 2

Details

Lead Sponsor:

Imunon

Collaborator:

Break Through Cancer Foundation

Treatments:

Bevacizumab
Carboplatin
Paclitaxel